Cardiac resynchronization therapy pacemaker: critical appraisal of the adaptive CRT-P device

Georges E Daoud \(^1\)
Mahmoud Houmsse \(^2\)

\(^1\)Department of the Biomedical Research, \(^2\)Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Abstract: Cardiac resynchronization therapy (CRT) is an effective and well-established therapy for patients suffering with heart failure, left ventricular (LV) systolic dysfunction (ejection fraction $\leq 35\%$), and electrical dyssynchrony, demonstrated by a surface QRS duration of $\geq 120$ ms. Patients undergoing treatment with CRT have shown significant improvement in functional class, quality of life, LV ejection fraction, exercise capacity, hemodynamics, and reverse remodeling of LV, and ultimately, morbidity and mortality. However, 30%–40% of patients who receive a CRT device may not show improvement, and they are termed nonresponders. The nonresponders have a poor prognosis; several methods have been developed to try to enhance response to CRT. Echocardiography-guided optimization of CRT has not resulted in significant clinical benefit, since it is done at rest with the patient in supine position. An ideal optimization strategy would provide continuous monitoring and adjustment of device pacing to provide maximal cardiac resynchronization, under a multitude of physiologic states. Intrinsic activation of the right ventricle (RV) with paced activation of the RV, even in the setting of biventricular (BiV) pacing, may result in an adverse effect on cardiac performance. With this physiology, the use of LV-only pacing may be preferred and may enhance CRT. Adaptive CRT is a novel device-based algorithm that was designed to achieve patient-specific adjustment in CRT so as to provide appropriate BiV pacing or LV-only pacing. This article will review the goals of CRT optimization, and implementation and outcomes associated with adaptive CRT.

Keywords: heart failure, cardiac resynchronization, therapy, adaptive, left and biventricular pacing

Introduction

Cardiac resynchronization therapy (CRT) is an effective and well-established therapy for patients suffering with heart failure (HF), left ventricular (LV) systolic dysfunction (ejection fraction $\leq 35\%$) and electrical dyssynchrony, demonstrated by a surface QRS duration of $\geq 120$ ms. Patients undergoing treatment with CRT have shown significant improvement in functional class, quality of life, LV ejection fraction (EF), exercise capacity, hemodynamics, and reverse remodeling of LV, and ultimately, morbidity and mortality. However, 30%–40% of patients who receive a CRT device may not show improvement, and they are termed nonresponders. The reasons for being a nonresponder are numerous and include, but are not limited to, scar burden and distribution, LV stimulation site, and limited electrical dyssynchrony.\(^{1,2}\)

Considering the risks and costs associated with implantation of a CRT device, and that nonresponders have a poor prognosis, several methods have been developed to try to enhance response to CRT. Echocardiography-guided optimization of
atrioventricular (AV) delay and interventricular (VV) delay between the LV and right ventricle (RV) was enthusiastically used to guide device programming. Unfortunately, though, echocardiography optimization (ECHO) has not resulted in significant clinical benefit because it is a time-consuming, resource-draining process and the parameters measured were often at rest with the patient in supine position. An ideal optimization strategy would provide continuous monitoring and adjustment of device pacing to provide maximal cardiac resynchronization, under a multitude of physiologic states.

Another important observation in device trials is that in the presence of intact AV conduction, LV dysfunction, and a narrow QRS, RV pacing results in deleterious effects due to pacing-induced dyssynchrony with subsequent increase in HF events and deterioration in left ventricular ejection fraction (LVEF). To date, the primary therapy of CRT has been simultaneous BiV pacing (ie, VV delay of 0); however, in the setting of intact AV conduction, this programming of CRT results in delivery of RV pacing, and thus substitutes intrinsic RV activation with RV-paced activation. Replacing intrinsic activation of the RV with paced activation of the RV, even in the setting of BiV pacing, may result in an adverse effect on cardiac performance. With this physiology, the use of LV-only pacing may be preferred and may enhance CRT.

Adaptive CRT (aCRT) is a novel device-based algorithm that was designed to achieve patient-specific adjustment in CRT so as to provide appropriate BiV pacing or LV-only pacing. This article will review the goals of CRT optimization, and implementation and outcomes associated with aCRT.

**Optimization**

Recognizing that up to 40% of patients fail to respond to CRT, there are numerous studies that have assessed methods to optimize response to BiV pacing, including lead position and echocardiography-guided programming of AV and VV intervals.

Rossillo et al evaluated 233 consecutive patients with New York Heart Association (NYHA) class III–IV HF and LVEF <35% who had successful placement of a transvenous LV lead. Outcomes (functional capacity and LVEF) were significantly improved in patients in whom the lead was placed in the lateral/posterolateral branch in comparison to the anterior and anterolateral branch.

Optimal AV delay has been an integral part of CRT therapy. Suboptimal AV delay programming can result in a 10%–15% decline in cardiac output; yet, the methods of optimization are varied: no optimization (CONTAK CD trial); Doppler echocardiography of transmitral flow (CARE-HF and MIRACLE trials); and, calculation of AV delay based on intrinsic AV delay and QRS duration (COMPANION trial). The SMART-AV trial was designed to compare a device-based algorithm, the SmartDelay, to echocardiography-guided AV delay optimization and to fixed nominal AV delay in a randomized pattern enrolling 1,014 patients. The primary end point in this study was LV end-systolic volume, and secondary end points included NYHA class, quality-of-life score, 6-minute walk distance, LV end-diastolic volume, and LVEF. The study concluded that neither SmartDelay nor echocardiography guidance was superior to a fixed AV delay of 120 ms. One likely explanation for why these sophisticated methods of AV optimization do not achieve improved results compared to nominal device programming is due to the dynamic nature of AV node physiology, at rest and with exertion. Considering the time and expense related to echocardiography-guided optimization, this technique is rarely utilized. Although maximizing AV timing offers important physiologic benefit and other studies have suggested that systematic AV interval optimization improves clinical outcomes, to date, there is no algorithm that reproducibly and reliably enhances AV timing with subsequent persistent hemodynamic benefit.

A third method to achieve optimal outcome from CRT is to alter VV timing. VV timing refers to the timing of delivery of electrical stimulus to the right and left ventricular leads, so as to alter interventricular activation. Conventional CRT is to deliver the stimulus simultaneously, BiV-0. In a prospective trial, enrolling 274 patients with NYHA class III–IV HF and who underwent CRT implantation, VV timing was randomized to simultaneous VV pacing (BiV-0) or to optimized VV timing based on echocardiography-guided assessment of LV septal to posterior wall motion delay during CRT. End points included a clinical composite end point of mortality: HF hospitalization, NYHA functional class, and patient global assessment, as well as 6-minute hall walk distance, quality of life, peak oxygen uptake, and event-free survival. The study found only modest but inconsistent benefit with optimized sequential VV stimulation, and this finding is similar to other studies investigating VV timing.

Methods to guide CRT device programming to enhance response to BiV pacing may have clinical relevance for those patients who do not respond to CRT; however, even among a population of nonresponders, the current techniques for optimization are not reliable or effective to manage the dynamic nature of cardiac conduction. Cardiac electrical events are altered by autonomic tone, drug therapy, ventricular volume/loading, and varied other factors such as exercise or upright...
posture. Optimization with one-time CRT device programming will not offer a lasting effect and, more importantly, will not respond to changes in cardiac conduction under a broad spectrum of conditions. Furthermore, although CRT is typically achieved with simultaneous BiV pacing, some studies have confirmed the value of LV-only pacing, which has been demonstrated to be at least as efficacious as BiV pacing and may be more effective. Other reports have evaluated the impact of LV pacing that is synchronized to RV activation in the setting of intact AV and right bundle branch conduction.\textsuperscript{12} LV pacing synchronized to normal RV activation produces electrical fusion of pacing activation of the LV with native RV activation and has been demonstrated to result in superior LV/RV stimulation and function compared to simultaneous BiV pacing.

A device-based algorithm that continuously alters device stimulation, LV only synchronized with native RV activation or BiV pacing, relative to measured intracardiac events is more likely to provide a dynamic physiologic response so as to maximize CRT, for responders as well as for nonresponders.

**Adaptive CRT algorithm**

Adaptive CRT (aCRT) is a novel pacing algorithm to provide continuous, dynamic, and ambulatory optimal CRT by measuring intracardiac conduction parameters, and then responding with either LV-only pacing, synchronized to RV activation, or simultaneous BiV pacing in the setting of abnormal AV/right bundle conduction. In this manner, the algorithm was developed to minimize RV pacing and the associated pacing-induced dyssynchrony, and in turn, to minimize nonresponders and to improve efficacy of CRT.

Adaptive CRT works by constantly measuring intracardiac timing events and altering pacing in response to three elements: intrinsic conduction, determination of the best pacing (LV-only or BiV), and optimization of AV and VV timing, in that sequence.

**Intrinsic conduction (AV interval, P-wave, and QRS interval)**

AV conduction interval is measured every minute by extending the AV delay to 300 ms for one beat. The timing is from either atrial sensed or atrial paced event to RV sensing (As-RVs or Ap-RVs). The P-wave conduction timing is measured from atrial sensing to the end of P-wave on the far-field atrial electrogram (A-Pend). The QRS duration is measured from RVs to the end of QRS on the far-field electrogram (RVs-QRSend). From these measurements, the P-wave interval and QRS duration are measured every 16 hours.

**Determination of the best pacing method**

First, capture of the LV lead is confirmed. Second is the determination of adaptive LV pacing or adaptive BiV pacing. If the sensed AV interval, As-RVs, is $\leq 200$ ms, or if the paced AV delay (Ap-RVs) is $\leq 250$ ms, and heart rate is $> 100$ bpm, then pacing is with adaptive LV pacing.

However, if the As-RVs is $> 200$ ms, or the Ap-RVs $> 250$ ms, and the heart rate is $> 100$ bpm, then adaptive BiV pacing is delivered.

**Optimization of AV and VV timing**

If adaptive LV pacing is selected, then the LV will pace at either 70% of the measured AV interval (As-RVs/Ap-RVs interval) or 40 ms before intrinsic A-RVs interval, whichever value is smaller. If adaptive BiV pacing is delivered, then BiV pacing will be 30 ms after the end of P-wave or 50 ms before intrinsic A-RVs interval, whichever is smaller.

The interventricular pacing delay (VV timing) during BiV pacing is calculated based on A-RVs as well as RVs-QRS end intervals. The shortest VV interval will be selected to allow LV preactivation. However, if the QRS is $> 160$ ms, then BiV-0 (simultaneous delivery of current to the RV and LV leads) pacing will be selected.

With these three steps, the goal of aCRT is to continuously measure the AV interval utilizing RV sensing (Figure 1).\textsuperscript{8} If right atrium to RV conduction is intact and normal, as represented by AV node + right bundle conduction, the algorithm provides LV-only pacing. In this manner, LV pacing is

---

**Figure 1** Summary of aCRT algorithm.

**Notes:** Reprinted from American Heart Journal, 163(5), Krum H, Lemke B, Birnie D, et al. A novel algorithm for individualized cardiac resynchronization therapy: rationale and design of the adaptive CRT trial, 747–752. Copyright (2012), with permission from Elsevier.\textsuperscript{8}

**Abbreviations:** aCRT, adaptive cardiac resynchronization therapy; AV, atrioventricular; LV, left ventricular; BiV, bi-ventricular; VV, interventricular; DDD/R, dual chamber pacemaker with and without rate response.

**Medical Devices: Evidence and Research downloaded from https://www.dovepress.com/ by 54.70.40.11 on 03-Apr-2019
For personal use only.**

**Submit your manuscript | www.dovepress.com**

---

**Dovepress**

Critical appraisal of the adaptive CRT-P device
synchronized to RV native activation to produce fusion with native right bundle activation. Since electrical conduction, particularly via the AV node, is dynamic, the AV delay is adjusted to produce optimal fusion with intrinsic activation. In this manner, the RV will be activated via intrinsic conduction, which averts the adverse physiology and dys-synchrony related to RV pacing. In the circumstances when AV conduction is poor, then BiV-0 pacing is provided with electrical stimulation based on optimizing AV delay, utilizing timing from the end of the P-wave. This aCRT algorithm is suspended during any sustained atrial or ventricular tachycardia, and is not applicable in the setting of complete heart block or AV junction ablation. Unpublished data about the accuracy of the automatic and manual measurement of the previously mentioned waves and intervals showed a mean error of 7 ms only in P-wave measurement (Medtronic Inc., personal communication, October, 2015).

**Clinical trials with aCRT**

The primary study investigating aCRT was by Martin et al, published in 2012. This was a prospective, multicenter, randomized, double-blind, “noninferiority” trial comparing outcomes of aCRT algorithm programmed ON versus simultaneous BiV pacing optimized by echocardiography. The study randomized 478 patients with HF who met criteria for de novo CRT system (NYHA Class III or IV symptoms, LVEF ≤35%, and QRS ≥120 ms). All patients first underwent an echocardiography-based AV and VV timing optimization. VV timing was guided by aortic velocity time integral (AoVTI), to measure stroke volume, and AV optimization by the iterative method. After echo-guided optimization, the aCRT software was downloaded into all devices. Patients were then randomized in a 2:1 manner to chronic pacing using aCRT versus ECHO.

Study follow-up was at 1, 3, and 6 months and then every 6 months thereafter. There were three primary end points at 6 months: 1) the clinical composite score (CCS) – an aggregate measure of death, hospitalization, and change in NYHA class, and patients were classified as improved, unchanged, or worsened; 2) the concordance correlation coefficient (CCC) between the AoVTI values measured for each patient under echo-optimized and aCRT exceeded 0.82 both at randomization and at 6-month post-randomization; and 3) safety of the ambulatory aCRT algorithm. Safety was defined as no more than 60 ms variance of the AV or VV delays throughout a 28-day period. If all primary end points were met, secondary end points were analyzed including: reduction of RV pacing in the aCRT arm, death, HF hospitalization, ventricular arrhythmias, changes in LV end-systolic volume index, LVEF, NYHA classification, 6-minute hall walk distance, and quality of life.

The aCRT study met all the three noninferiority primary end points. The percentage of patients who improved in the CCS at 6 months was 73.6% for aCRT versus 72.5% for ECHO (Figure 2; noninferiority P<0.0007); the CCC at randomization and at 6-month follow-up was high, 0.93 and 0.90, respectively (Figure 3); and aCRT did not result in inappropriate device settings. During a mean follow-up of 9.7 months, there were no differences in mortality or HF events and no difference in time to first occurrence of HF or of ventricular arrhythmias between the study groups. Other secondary end points are summarized in Table 1. In the ECHO group, nearly all ventricular pacing was BiV, whereas in the aCRT group, median of the occurrence of BiV pacing was 51% and the remainder was LV-only pacing, with a 44% reduction in RV pacing. The study concluded that aCRT was safe and noninferior to echocardiography-guided optimization.

Two post hoc analysis procedures were considered for the aCRT trial. The first study compared the treatment arm of aCRT (n=266) to a pooled historical control (HC) group

---

**Figure 2** Summary of aCRT study.


**Abbreviation:** aCRT, adaptive cardiac resynchronization therapy.

**Figure 3** Summary of aortic velocity time integral (AoVTI) at randomization and at 6-months follow-up comparing aCRT to echo-guided optimization.


**Abbreviations:** aCRT, adaptive cardiac resynchronization therapy; CCC, concordance correlation coefficient.
Critical appraisal of the adaptive CRT-P device

(n=485) derived from the CRT arms of four clinical trials (MIRACLE, MIRACLE ICD, PROSPECT, and InSync III Marquis), which each provided BiV-0 pacing. The study end point was to assess change in the CCS at 6-month follow-up. Patients in the HC underwent echocardiography-guided AV optimization. The adjusted absolute difference (in percent) improved in CCS between the aCRT and HC arms was 11.9% (95% confidence interval [CI]: 2.7%–19.2%) favoring aCRT, and aCRT patients were significantly more likely to have an improved CCS when compared to HC (odds ratio [OR] = 1.65, 95% CI: 1.1–2.5) (Figure 4). The implication from this study is that aCRT is better, rather than noninferior, to echo-guided AV optimization.

In the second post hoc analysis, patient outcomes in the aCRT trial were correlated to percent of synchronized LV pacing as a percentage of total ventricular pacing over the 12-month follow-up (n=318). The adjusted absolute difference in percent synchronized left ventricular pacing in the aCRT arm was 10.9% (95% CI: 5.4%–16.3%, p<0.0001) when compared to the HC arm. Patients with a lower percentage of LV pacing were less likely to benefit from aCRT, with a 23% improved CCS at 6 months compared to 36% in patients with >50% LV pacing (Figure 5).
Outcomes were also compared in the aCRT group versus control patients (BiV-0 pacing) stratified by intrinsic AV interval. When synchronized LV pacing was ≥50% in the aCRT group (n=142/314, 45%), there was a significant reduction in risk of death or HF hospitalization (hazard ratio [HR] 0.49; 95% CI 0.28–0.85; P=0.012) compared to when synchronized LV pacing was <50% (Figure 5). Also, in the patients with normal AV conduction (n=241), the risk of HF hospitalization was lower in those patients treated with aCRT rather than BiV-0 (HR 0.52; 95% CI 0.27–0.98; P=0.044). This study concluded that a greater degree of synchronized LV pacing and aCRT in patients with normal AV intervals were independently associated with improved clinical outcomes.

Starling et al completed a prospective evaluation of the original aCRT study population, assessing hospitalization for HF and for all causes with readmission within 30 days. The mean follow-up was 20.2 months, far greater than the 9.7-month follow-up in the original aCRT study. For HF hospitalizations, the 30-day readmission rate was 19.1% (17 of 89) in the aCRT group and 35.7% (15 of 42) in the ECHO group (BiV-0 pacing) (OR 0.41; 95% CI 0.19–0.86; P=0.02) (Figure 6). For all-cause hospitalization, the 30-day readmission rate was 14.8% (35 of 237) in the aCRT group compared with 24.8% (39 of 157) in the ECHO group (OR 0.54; 95% CI 0.31–0.94; P=0.03). The conclusion was that aCRT therapy was associated with a significant reduction in 30-day readmission after both HF and all-cause hospitalizations.

Conclusion and clinical implications
Modifying electrical activation of the heart with CRT has been demonstrated to be successful at enhancing cardiac performance. Yet, this field is still young and the ideal methods for electrical stimulation are unclear. An initial approach for optimization utilized echocardiography to guide electrical events by measuring changes in mechanical activation. Yet this technique has modest benefit. Another attempt to improve electrical stimulation is with electrocardiographic optimization, but this is limited by variable response and is a one-time device programming.

Adaptive CRT represents the next step in investigating best CRT pacing techniques. The algorithm was designed to provide device-based, continuous assessment and automated dynamic alteration of electrical events. The basic premise is to avoid RV pacing in patients with normal AV and right bundle conduction, and in this manner provide only the required therapy, synchronized LV stimulation, to help correct delayed left bundle activation. Simultaneous BiV pacing is utilized for patients with poor AV node – right
bundle conduction. Adaptive CRT, therefore, is another step toward favoring LV stimulation. Although clinical trials to date demonstrate improved outcomes, including mortality, with aCRT, the entirety of the findings is based upon one randomized trial. Also, aCRT is only applicable in ~40% of recipients of CRT, since it requires sinus rhythm, and intact AV node and right bundle conduction. Before embracing and building upon aCRT as the foundation for a new direction of electrical stimulation for HF, larger multicenter, randomized trials are necessary to not only confirm the benefits of aCRT, but also to compare aCRT to LV-only pacing. We also need to keep in mind the financial impact of the newer technology in CRT including adaptive CRT. The cost of the aCRT device compared to the nonadaptive CRT device is slightly higher. Our hospital purchasing department pays an extra $2,070 for the aCRT system.

Disclosure
Mahmoud Houmsse receives researching funding from Medtronic. The authors report no other conflicts of interest in this work.

References